. 2018 May 3;9:907. doi: 10.3389/fimmu.2018.00907

Table 3.

Comparison of immunological markers across the three subject groups.

Immunological marker	Subject cohort			3-Way comparison

	Control	Active	Remission	Summary p-value
T-cell subsets (%) and ratios
CD25⁺FoxP3⁺ T-regulatory cell (Treg)	5.6 (5.3–6.7)	4.4 (3.6–6.0)	7.1 (5.8–8.3)	0.000^***
CD25⁺TIGIT⁺FoxP3⁺ Treg	4.2 (3.3–4.4)	2.5 (2.1–4.3)	5.0 (4.2–5.9)	0.000^***
TIGIT⁺FoxP3⁺:TIGIT⁺FoxP3⁻	0.6 (0.5–0.7)	0.4 (0.2–0.6)	0.6 (0.5–0.8)	0.049^*
TIGIT⁺FoxP3⁺CD25⁺:TIGIT⁺FoxP3⁻	0.5 (0.4–0.6)	0.3 (0.1–0.4)	0.7 (0.5–0.9)	0.003^**
Th1 (T-bet⁺)	57.1 (40.8–66.4)	58.6 (48.8–72.2)	48.5 (42.7–55.9)	0.025^*
Th17 (RORγt⁺)	2.4 (1.2–4.5)	1.5 (0.8–4.4)	1.7 (1.2–3.2)	0.564
Treg:Th1	0.7 (0.6–0.8)	0.4 (0.3–0.6)	0.7 (0.5–0.9)	0.000^***
Treg:Th17	0.4 (0.2–0.4)	2.0 (0.8–3.5)	2.8 (1.5–4.3)	0.001^**
T-bet⁺FoxP3⁺	0.7 (0.5–0.8)	0.7 (0.5–1.2)	1.1 (1.0–1.6)	0.000^***
RORγt⁺FoxP3⁺	0.6 (0.5–0.9)	0.5 (0.1–0.7)	0.6 (0.3–1.1)	0.363
RORγt⁺T-bet⁺	1.5 (0.6–2.5)	1.0 (0.4–2.0)	1.5 (0.9–2.3)	0.183

Serum cytokine levels (pg/mL)
IL-10	24.2 (22.8–25.4)	11.6 (9.8–11.8)	21.5 (20.0–22.8)	0.000^***
Transforming growth factor β	56.9 (38.9–85.4)	62.7 (48.7–96.5)	161.1 (122.5–285.2)	0.001^**
IFN-γ	208.4 (197.3–214.4)	408.8 (404.8–418.8)	297.8 (296.1–299.5)	0.000^***
IL-17	13.9 (13.2–14.0)	14.8 (13.9–15.9)	13.0 (11.9–13.4)	0.003^**
IL-22	19.9 (17.3–20.2)	20.6 (20.3–22.0)	18.3 (17.1–18.8)	0.002^**

CpG site methylation levels (%)
FOXP3 promoter	69 (52–75)	72 (66–77)	53 (46–68)	0.037^*
FOXP3 Treg-specific demethylated region	69 (61–71)	76 (68–83)	63 (59–67)	0.005^**
TIGIT	54 (47–55)	59 (57–64)	48 (46–53)	0.004^**
TBX21/T-BET	0.7 (0.6–0.8)	0.4 (0.3–0.5)	0.7 (0.5–0.8)	0.122
RORC2/RORγT	55 (52–61)	46 (44–51)	55 (51–58)	0.006^*

Median values are in bold font.

*Significant at the 5% level.

**Significant at the 1% level.

***Significant at the 0.1% level.